RecruitMe Clinical Trial

An Open-label, Multicenter Phase Ib Study of the Safety and Tolerablility of Atezolizumab (ANTIPD-L1 Antibody) Administered in Combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors
A Study for Patients with Solid Tumors Using Study Drug Atezolizumab
Sponsor:Genentech, Inc.
Enrolling:Male and Female Patients
Age Range:Between 18 and 99 years old
IRB Number:AAAQ7567
U.S. Government ID:NCT02715531
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Do You Qualify?
Have you been diagnosed with gastric cancer or metastatic pancreatic cancer?YesNo
Submit
Cancel
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162